Pfizer agrees to acquire Palo Alto-based Anacor Pharmaceuticals for $99.25 per share or $5.2B net of cash. The deal should close in Q3. Anacor is the exclusive U.S. distributor of Sandoz's PharmaDerm's Kerydin (tavaborole) topical solution 5%, the first oxaborole antifungal indicated for the treatment of toenail fungal infection. Its lead product candidate is crisaborole topical ointment 2% for the treatment of atopic dermatitis. Its New Drug Application (NDA) is currently under FDA review. The PDUFA date is January 7, 2017. Pfizer believes peak sales could reach $2B, according to Seekig Alpha. Check this out, Anacor shares are just skyrocketing today! 55 per cent jump Meanwhile Pfizer shares are keeping calm. I don't expect this deal to influence the giant's stock in any way... Pfizer is a steady "hold" for me $PFE, Pfizer, Inc. / 1440